These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Status and prospects of gene therapy for urologic cancer. Kumon H Mol Urol; 2000; 4(2):39-40. PubMed ID: 12006238 [No Abstract] [Full Text] [Related]
9. Assessment of adenoviral vector safety and toxicity: report of the National Institutes of Health Recombinant DNA Advisory Committee. Hum Gene Ther; 2002 Jan; 13(1):3-13. PubMed ID: 11779411 [No Abstract] [Full Text] [Related]
10. Status and prospects of gene therapy for urologic cancer. First Meeting of the Japanese Society for Urological Gene Therapy. November 20, 1999. Okayama, Japan. Mol Urol; 2000; 4(2):37-87. PubMed ID: 12362879 [No Abstract] [Full Text] [Related]
11. Application of conditionally replicating herpes vector for gene therapy treatment of urologic neoplasms. Oyama M; Yazaki T; Ohigashi T; Hoshi M; Horiguchi Y; Oya M; Asakura H; Nakashima J; Tachibana M; Uyemura K; Murai M Mol Urol; 2000; 4(2):83-7. PubMed ID: 12006247 [TBL] [Abstract][Full Text] [Related]
18. Potential risk of inadvertent germ-line gene transmission statement from the American Society of Gene Therapy to the NIH Recombinant DNA Advisory Committee, March 12, 1999. Wilson JM; Wivel NA Hum Gene Ther; 1999 Jun; 10(9):1593-5. PubMed ID: 10395383 [No Abstract] [Full Text] [Related]
19. NIH Recombinant DNA Advisory Committee data management report. June 18-19, 1998. Hum Gene Ther; 1998 Sep; 9(14):2143-61. PubMed ID: 9759940 [No Abstract] [Full Text] [Related]
20. Surgical consolidation of initially unresectable urothelial carcinoma: an incremental opportunity to cure. Siefker-Radtke AO Expert Rev Anticancer Ther; 2009 Dec; 9(12):1701-3. PubMed ID: 19954279 [No Abstract] [Full Text] [Related] [Next] [New Search]